Vir Biotechnology DEF 14A: Executive Compensation Details
Ticker: VIR · Form: DEF 14A · Filed: Apr 17, 2025 · CIK: 1706431
| Field | Detail |
|---|---|
| Company | Vir Biotechnology, Inc. (VIR) |
| Form Type | DEF 14A |
| Filed Date | Apr 17, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, board-of-directors, equity-awards
Related Tickers: VIR
TL;DR
Vir Bio's DEF 14A drops, showing exec pay & equity awards for 2024. Scangos & DeBacker compensation detailed.
AI Summary
Vir Biotechnology, Inc. filed a DEF 14A on April 17, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and board member information, including compensation for Dr. Scangos and Dr. DeBacker for the years 2020 through 2024. It also outlines equity awards granted to both PEO and Non-PEO NEO members.
Why It Matters
This filing provides transparency into how Vir Biotechnology compensates its top executives and board members, which can influence investor perception and company governance.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing detailing executive compensation and board information, not indicating any immediate operational or financial risks.
Key Numbers
- 2024 — Fiscal Year End (The period for which compensation and equity awards are detailed.)
- 2020-2024 — Compensation Reporting Period (The range of years for which executive compensation data is provided.)
Key Players & Entities
- Vir Biotechnology, Inc. (company) — Filer of the DEF 14A
- Dr. Scangos (person) — Executive/Board Member mentioned in compensation details
- Dr. DeBacker (person) — Executive/Board Member mentioned in compensation details
- 1800 Owens Street, Suite 900, San Francisco, CA 94158 (location) — Company's business and mailing address
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by a company to solicit proxies from shareholders for an upcoming annual or special meeting. It provides detailed information about matters to be voted on, including executive compensation, director elections, and other corporate governance issues.
Who are the key individuals whose compensation is detailed in this filing?
The filing details compensation and equity awards for individuals identified as 'Dr. Scangos' and 'Dr. DeBacker', who are associated with equity awards for PEO (Principal Executive Officer) and Non-PEO NEO (Non-Principal Executive Officer Named Executive Officer) roles.
What is the reporting period covered by the compensation information?
The compensation information and equity awards detailed in this filing cover the fiscal years from 2020 through 2024.
What type of equity awards are mentioned in the filing?
The filing mentions 'EqtyAwrdsInSummryCompstnTblForAplblYrMember' (Equity Awards in Summary Compensation Table for Applicable Year Member) and 'YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember' (Year-End Fair Value of Equity Awards Granted in Covered Year Outstanding and Unvested Member), indicating grants of equity awards.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 17, 2025.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 17, 2025 by Dr. Scangos regarding Vir Biotechnology, Inc. (VIR).